Castle Biosciences : Corporate Presentation January
January 13, 2021 at 09:38 am EST
Share
The Skin Cancer Diagnostics Company
COMPANY PRESENTATION
January 2021
NASDAQ: CSTL
DISCLAIMERS
Forward-LookingStatements
The information in this presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. These forward-looking statements include, but are not limited to, statements concerning the effects of the COVID-19 pandemic on our business and our efforts to address its impact on our business, our anticipated milestones, estimated total addressable market attributable to our pipeline products, and our plans for commercial expansion, including anticipated number of sales territories. The words "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in our Annual Report on Form 10-K for the year ended December 31, 2019, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.
DecisionDx, DecisionDx-UM,DecisionDx-Melanoma,DecisionDx-SCC, DecisionDx DiffDx-Melanoma and the Castle Biosciences logo are the registered trademarks of Castle Biosciences, Inc. This presentation may also contain trademarks and trade names that are the property of their respective owners.
2
The Skin Cancer Diagnostics Company
PRELIMINARY Q42020 INFORMATION
January 2021
NASDAQ: CSTL
Preliminary Fourth Quarter and Year-end 2020 Performance Results1 (unaudited)
11 peer-reviewed articles published in 2020 to support adoption of our tests by clinicians and reimbursement by commercial payers
Strong Balance Sheet
Year-end2020 cash and cash equivalents of ~$410 million2
No debt
1 Castle will report full financial results in March 2021.
2 This amount is preliminary and is subject to completion of financial closing procedures. As a result, this amount may differ from the
4
amount that will be reflected in our financial statements as of and for the year ended December 31, 2020.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Castle Biosciences Inc. published this content on 13 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 January 2021 14:37:01 UTC
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.
CASTLE BIOSCIENCES, INC. 
